BIONIK LABORATORIES CORP. (OTCMKTS:BNKL) Files An 8-K Regulation FD Disclosure
Item 7.01
|
Regulation FD Disclosure
|
issued a press release regarding that it has been made aware of
and requested by the OTC Markets Group, Inc. to comment on recent
trading and promotional activity concerning its common stock.
Current Report on Form 8-K and is incorporated herein by
reference. The information in this report (including Exhibit
99.1) is being furnished to Item 7.01 and shall not be deemed to
be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section. This report will not be deemed an
admission as to the materiality of any information herein
(including Exhibit 99.1).
|
Item 9.01
|
Financial Statements and Exhibits
|
About BIONIK LABORATORIES CORP. (OTCMKTS:BNKL)
Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., is a medical device and robotics company. The Company is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Company is also engaged in developing a lower-body exoskeleton, ARKE, which designs to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking. BIONIK LABORATORIES CORP. (OTCMKTS:BNKL) Recent Trading Information
BIONIK LABORATORIES CORP. (OTCMKTS:BNKL) closed its last trading session down -0.155 at 0.455 with 2,000 shares trading hands.